Groundbreaking healthcare technologies to revolutionize global health and improve human health

BOSTON - July 27, 2016 - PRLog -- Following two decades of revolutionary and groundbreaking developments in cosmetic and pharmaceutical packaging device development, including the globally acclaimed Single Vial System (SVS) technology, Prof. Dr. S Tsakas II, along with his father Prof. Dr. S Tsakas Sr., announces today some exciting news and updates from the scientific partnership that has been in operation since the early 1990s. Recently, the SVS technology has been endorsed, sponsored and funded by the Bill & Melinda Gates Foundation, World Health Organization, Prince's Trust, Scottish Enterprise and the Royal Society of Edinburgh for its ability to deliver twice as many medicines at half the cost worldwide.

SVS Medical LLC, based in the Greater Boston area, has recently acquired all IP rights to both BioFaran Laboratories S.A. and Eulysis Inc. and their respective Single Vial System (SVS) technology developments. Thus, two decades of experimental development through to market launched and proven technologies are imminently to be available in the US market and beyond. Speaking of the recent agglomeration of companies and technologies, Prof. Dr. S Tsakas II highlighted the ease of operations and streamlining offered by the recent move. "Undoubtedly, Cambridge, along with the Greater Boston area biotech hub, is one of the powerhouses internationally for stimulating, developing and launching breakthrough advances in healthcare. Our dreams of developing useful technologies to solve real world problems ranging from acute skin conditions through to chronic healthcare management have led to this apex - SVS Medical LLC. Through this vehicle, we intend to offer both companies' technological developments to the market and extrapolate the key benefits to the global audience from our US base of operations."

In addition, STFIH Group has been formed by the father-son duo while including long-time trusted scientific advisor and colleague Prof. Dr. Grahame Bulfield, CBE, FRSE, into the founding team. STFIH Group is to act as the investment fundraising medium for SVS Medical LLC and the remaining businesses developed by S Tsakas Sr. and S Tsakas II. While these shifts indicate new and exciting times ahead, the founders truly hope to capitalize on the recent turnaround in global markets and expand pharmaceutical access globally through Eulysis' pharmaceutical packaging solution for parenteral SVS applications.

Prof. Dr. S Tsakas Sr. is quoted, "Our vision was always to improve global health - in any state, shape or form we could. Starting from this vantage and perspective, we were always going to apply technologies with user-led elements incorporated to optimize satisfaction, adherence and efficacy of our treatments. I believe we are in a prime location, time and position to seize new opportunities and lead our technologies to the industry giants that can successfully mass market launch our innovations and propel healthcare to new heights. We welcome new contacts from interested parties to collaborate on this new venture."

For more information, please visit www.svsmedical.com or www.stfih.com.

Ross Tsakas, rt@svsmedical.com and rt@stfih.com Tel: +1 774 463 9947